Navigation Links
Spherix Announces Registered Direct Offering of $2.77 Million
Date:1/20/2011

ed clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. Spherix Elects New Independent Director, and Elects Chairman of the Board
7. Spherix Reports First Quarter 2009 Earnings
8. Spherix Announces Positive Phase 2 Study Results
9. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
10. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
11. Spherix Reports Third Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... on August 29, 2011, as Vice President, Finance and Chief ... Arena for over 13 years before departing in March to ... a valuable leader who has been a key contributor to ...
... 2011 5 modules - 2 weeks - ... to announce that the Stability Testing Online Training Course is proving ... ,The secret behind the Stability testing Online Training Course ... is its user-friendly format which allows flexible and interactive high standard, ...
Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Stability Testing Course is Taking the Online Training Format by Storm! 2
(Date:7/22/2014)... American Society of Hematology (ASH) will present the Society,s ... Lifetime Achievement in Hematology, to Kanti R. Rai, MD, ... of Medicine for his 50-year career combining landmark clinical ... exceptional patient care. , The Wallace H. Coulter ... an individual who has been a vital contributor to ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... 27 Ten Big Brothers Big Sisters agencies will receive ... "engaging parents as partners" to help children improve their odds ... Sisters is the nation,s largest donor-supported volunteer mentoring network with ... incarcerated parents, with a focus on breaking negative cycles. ...
... , , ISELIN, N.J., Aug. 27 ... for PharmSep: LCGC,s Symposium for Separation Scientists in Pharmaceuticals. The ... DeLand, Pharmaceutical Market Development Manager, Dionex Corporation , and ... will take place in Philadelphia, PA, on September 21-22, 2009. ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... organization has signed a Master Services Agreement (MSA) to use ... Thorough QT (TQT) and Phase 1 studies delivered by its ...
... Dr. ... win the battle against the epidemic of untreated sleep apnea by offering special incentives to ... ... Southern California sleep apnea expert, has found a way to help patients win the battle ...
... ... Announcing an exciting innovation in antimicrobial coatings: OxiTitan VLR. The ... power of light. Durable and easily applied to existing interior surfaces ... utilizing normal incandescent or flourescent lighting. The continuously active photocatalyst traps ...
... ... reduce operating costs and improve efficiencies for homecare providers. , ... (Vocus) August 27, ... improve productivity for homecare providers., , , , ,According to Spencer Kay, President ...
Cached Medicine News:Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 2Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 3Health News:LCGC Announces the Agenda for Their Upcoming PharmSep Conference 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 3Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 4Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 2Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 3Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 2Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 3Health News:New Fastrack Technology Improves Productivity 2Health News:New Fastrack Technology Improves Productivity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: